News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ilypsa, Inc. Appoints Samuel R. Saks, M.D. To Board Of Directors


12/5/2006 10:55:02 AM

SANTA CLARA, Calif.--(BUSINESS WIRE)--Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal and metabolic disorders, today announced that Samuel R. Saks, M.D., Chief Executive Officer, Jazz Pharmaceuticals, will be joining Ilypsa’s Board of Directors.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES